Nonne ego umquam tibi hoc, Jurassic Park, Jurassic Dominium Mundi, Sam neill
Sam Neill, "Jurassic Park" actor, cum cancro sanguine diagnostus est
Martii 2023: Primum caput scriptoris Sam Neill incursus formidolosus esset alicui qui ante notitiam eius non habuit. Ridiculam satis incipit: magnum tinctum de Elena filia eius interrogatus de jo. patris sui.
CAR T Cell Lorem iudiciis, multa myeloma iudiciis
Orci iudicium de CAR-T Cell Lorem aegrotis cum BCMA/TACI-positivis relapsis et/vel refractariis myeloma multiplex
Brevis Summarium: APRILIS CAR-T studium cellularum curationum aegris cum BCMA/TACI positivo relapso et/vel refractorio multiplex myeloma Detailed Descriptio: Hoc brachium unicum est, pittacium apertum, si ..
AZA-JMML-001, Celgene Corporation, myelomonocytic leukemia juvenile, NCT02447666, Vidaza
Azacitidine probatur a FDA pro myelomonocytico leukemia juvenili nuper dignosci
Iunii 2022: FDA azacitidinem medicamentorum (Vidaza, Celgene Corp.) pro pueris nuper praecognitis myelomonocytica leukemia juvenili (JMML) approbavit pharmacokinetica, pharmacodynamica, salus, et actio azacitidinis p.
TNF, CARVYKTI, ciltacabtagen autoleucel, agente immunomodulatory, Janssen Biotech, proteasome Matrix
Ciltacabtagen autoleucel approbatur pro relapsus vel refractorio multiplex myeloma
Martii 2022: Post quattuor vel plures priores lineas therapiae, inhibitor proteasome (PI), agens immunomodulatorius (IMiD), et anti-CD38 monoclonalis anticorpus, Cibus et medicamentum Administration approbavit ciltacabtagne au.
Studium suadeant CAR T-Cell curationem efficacem, ut curationem primam lineae pro magno periculo magnae lymphoma B-cell
Martii 2022: Universitas Texas MD Anderson Cancer Centrum investigatores indagatores axi-cel, anti CD19 antigenum receptorem chimaericum autologum (CAR T-cell theraphim) tutam et efficacem esse curationem primigenii aegris ingenii.
Burkitt lymphoma, Burkitt-sicut lymphoma, DLBCL, Genentech, Rituxan, Rituximab
Rituximab plus chemotherapy probatur ex FDA ad indicia cancri pediatrici
Martii 2022 : Cibus et medicamentum administrationis rituximab (Rituxan, Genentech, Inc.) approbavit in coniunctione cum chemotherapy pro CD20-positiva diffusa lymphoma magna B-cella (DLBCL), Burkitt lymphoma (BL), Burkitt-lymphoma simile.
Amgen, carfilzomib', Darzalex Faspro, dexamethasone, Janssen Biotech, Kyprolis, multa myeloma
Darzalex faspro, kyprolis, et dexamethasone approbatur a FDA pro myeloma multiplex.
March 2022: Daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) et carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone a Cibus et medicamentis administrationis adultis aegris relap .
Efficax therapiae CAR T-Cell contra magnum periculum magnum B-Cell lymphoma
Dec 2020: Universitas Texas MD Anderson Cancer Centrum investigatores indagatores axi-cel repertum, anti- CD19 antigenum chimaericum receptorem (CAR) T cellam curationem tutam et efficacem esse curationem primi-lineae aegris cum .
Asciminib, longis myeloideis leukemia, laboratorium Novartis AG, Ph+ CML, Philadelphia chromosomatum, Scemblix
Asciminib approbatur Philadelphiae chromoso-positiva chronica myeloidea leukemia
Nov 2021: Asciminib (Scemblix, Novartis AG) approbatione accelerata data est Administrationis Cibus et medicamentis aegris cum Philadelphia chromoso-positiva chronica myeloidalis leukemia (Ph+CML) in periodo chronica (CP) qui pr.
SPHERA, Brexucabtagenes autoleucel, milvus tecta, Tecartus, ZUMA-3
Brexucabtagenum autoleucelum approbatur a FDA pro relapso vel refractorio B-cello praecursori acuto lymphoblastico leukemia
Octobris 2021 : Brexucabtagne autoleucel (Tecartus, Milvus Pharma, Inc.) approbata est ab Administratione Cibus et medicamentis adultis aegris relapsis vel refractoribus B-cell praecursoribus acutis leukemia lymphoblastica (ALL). In..